首页> 美国卫生研究院文献>Oncotarget >Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing
【2h】

Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing

机译:通过靶向扩增子序列分析日本患者口腔鳞状细胞癌中与癌症相关的基因突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Somatic mutation analysis is a standard practice in the study of human cancers to identify mutations that cause therapeutic sensitization and resistance. We performed comprehensive genomic analyses that used PCR target enrichment and next-generation sequencing on Ion Proton semiconductor sequencers. Forty-seven oral squamous cell carcinoma (OSCC) samples and their corresponding noncancerous tissues were used for multiplex PCR amplification to obtain targeted coverage of the entire coding regions of 409 cancer-related genes (covered regions: 95.4% of total, 1.69 megabases of target sequence). The number of somatic mutations in 47 patients with OSCC ranged from 1 to 20 with a mean of 7.60. The most frequent mutations were in TP53 (61.7%), NOTCH1 (25.5%), CDKN2A (19.1%), SYNE1 (14.9%), PIK3CA (10.6%), ROS1 (10.6%), and TAF1L (10.6%). We also detected copy number variations (CNVs) in the segments of the genome that could be duplicated or deleted from deep sequencing data. Pathway assessment showed that the somatic aberrations within OSCC genomes are mainly involved in several important pathways, including cell cycle regulation and RTK–MAPK-PI3K. This study may enable better selection of therapies and deliver improved outcomes for OSCC patients when combined with clinical diagnostics.
机译:体细胞突变分析是人类癌症研究中用于识别引起治疗性敏化和耐药性的突变的标准实践。我们进行了全面的基因组分析,这些分析在Ion Proton半导体测序仪上使用了PCR靶标富集和下一代测序。使用47个口腔鳞状细胞癌(OSCC)样品及其相应的非癌组织进行多重PCR扩增,以靶向覆盖409个癌症相关基因的整个编码区域(覆盖区域:占总数的95.4%,目标为1.69兆碱基)序列)。 47例OSCC患者的体细胞突变数范围为1至20,平均为7.60。突变最频繁的是TP53(61.7%),NOTCH1(25.5%),CDKN2A(19.1%),SYNE1(14.9%),PIK3CA(10.6%),ROS1(10.6%)和TAF1L(10.6%)。我们还检测了基因组区段中的拷贝数变异(CNV),这些变异可以从深度测序数据中复制或删除。途径评估表明,OSCC基因组内的体细胞畸变主要涉及几个重要途径,包括细胞周期调控和RTK-MAPK-PI3K。这项研究可以使OSCC患者更好地选择治疗方法,并结合临床诊断方法改善治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号